
Naltrexone vs Ozempic for Alcohol and Weight: Need Both?
By Rethink Drink. For UK adults. Reviewed November 2026.
Naltrexone is a prescription medicine that blocks the brain's opioid receptors. In the UK, it's licensed for alcohol dependence. On its own, it isn't a weight-loss medicine.
Ozempic (semaglutide) is a diabetes medicine. Its sister brand, Wegovy, is for weight loss. Neither is licensed for alcohol... but trials are now testing whether medicines like it help people drink less.
One is used for alcohol today. The other is a promising question.
Maybe you're just starting to look into this. Or maybe you're already on a weight-loss injection, you've noticed you're drinking less, and you're wondering whether you need naltrexone too.
This page explains medicines. It doesn't recommend any of them. Whether one is right for you is a decision for a prescriber who knows your health.
In short
Naltrexone blocks part of alcohol's reward. In the UK, it's licensed to help people who have stopped drinking stay stopped.
It isn't a weight-loss medicine on its own. A combination tablet, naltrexone with bupropion (Mysimba), is licensed for weight management, but NICE doesn't recommend it on the NHS.
Ozempic, Wegovy and Mounjaro are GLP-1 medicines for type 2 diabetes or weight. None is licensed for alcohol.
The alcohol evidence for GLP-1s is early. A handful of small trials, with mixed results. Big health-record studies show a link with less alcohol harm, but a link isn't proof.
Is one better for drinking less? Nobody can honestly say yet. They've never been tested head to head.
Check first: if your body depends on alcohol, stopping or cutting down too fast can be dangerous. Speak to your GP (General Practitioner) or local alcohol service before you change anything...
...Our free units calculator and AUDIT-C check give you a starting picture in a couple of minutes. They can't tell you whether your body depends on alcohol; a doctor can.
Naltrexone vs Ozempic at a glance
Naltrexone | Ozempic (semaglutide) | |
|---|---|---|
What it is | Opioid blocker | GLP-1 medicine (copies a gut hormone) |
UK licence | Alcohol dependence (relapse prevention, craving) | Type 2 diabetes. Not alcohol |
Licensed for weight loss? | Not on its own | Not as Ozempic. Yes as Wegovy |
How it's thought to help with alcohol | Blocks part of alcohol's reward | Still being researched |
Alcohol evidence | Decades of trials; a real, modest effect | A handful of small trials since 2022 |
How it's taken | Tablet, as your prescriber decides | Injection, as your prescriber decides |
A table can't tell you what's right for you. It's a starting point for a conversation with a doctor.
What is naltrexone, and what is it used for?
Naltrexone is a prescription-only tablet, an opioid antagonist. In plain words... when you drink, your brain releases endorphins, its own feel-good chemicals. They land on opioid receptors, and that provides a reward. Naltrexone sits on those receptors and blocks them, so the endorphins have almost nowhere to land, which is how the reward cycle is interrupted.
The UK product information for Adepend, a naltrexone brand licensed for alcohol (now discontinued), says it's used as part of a comprehensive programme of treatment to reduce the risk of relapse, support abstinence and reduce the craving for alcohol.
It isn't a "makes you sick if you drink" medicine (that's disulfiram), and the same product information says it doesn't lead to dependence.
Naltrexone can be used in two completely different ways:
On the NHS: once you've stopped drinking, to help you stay stopped. That's its licensed use.
On The Sinclair Method: before drinking, at a time your prescriber sets, while you're still drinking. With the reward blocked, every drink is a shift with no pay... so over time, the aim is that the desire weakens and you drink less. Or stop, if you choose to. That use is off-label in the UK, which is one reason many GPs won't prescribe it: Can I get naltrexone from my GP?
It's not the medication itself that makes the method, it's the protocol of how to take it: What is The Sinclair Method?
The full explainer: Naltrexone for alcohol in the UK: what it is and how it works.
Is naltrexone used for weight loss?
On its own, no. Naltrexone isn't licensed for weight loss in the UK.
What you may have seen is Mysimba, a tablet that combines naltrexone with another medicine, bupropion. Its UK product information says it's for weight management in adults above a certain BMI (body mass index), alongside diet and more physical activity.
But in 2017, NICE (the body that advises what the NHS funds) said it is "not recommended" for managing overweight and obesity (NICE's decision). So in practice, it's private, if a doctor thinks it's right for you.
And it isn't an alcohol medicine. Its own product information says alcohol should be minimised or avoided while taking it, and it must not be used by people going through acute alcohol withdrawal.
Same ingredient. Different medicine. Different job.
What does Ozempic actually do?
Ozempic is semaglutide, a GLP-1 medicine. It copies a gut hormone.
The NHS lists three semaglutide brands: Ozempic (an injection, for type 2 diabetes), Wegovy (an injection, for weight loss) and Rybelsus (a tablet, for type 2 diabetes). For weight, it reduces appetite and helps you feel full for longer. For diabetes, it helps lower blood sugar.
Mounjaro (tirzepatide) is a close cousin that acts on two gut hormones, GLP-1 and GIP, for type 2 diabetes or obesity.
In the UK, Ozempic is used for type 2 diabetes. None of these medicines is licensed for alcohol.
Does Ozempic help you drink less? What the evidence says
It might. Here's what the trials found, in order.
Exenatide, 2022 (Denmark). An older GLP-1 medicine, tested in 127 people with alcohol use disorder for 26 weeks, alongside talking therapy. Overall, it didn't reduce heavy drinking days compared with a dummy injection. In an exploratory group with obesity, it did (Klausen and colleagues).
Semaglutide, 2025 (US). 48 adults with alcohol use disorder, who weren't seeking treatment, for nine weeks. They drank less in a lab session, had fewer drinks on drinking days, and reported less craving. But how often they drank, and average drinks per day, didn't change (Hendershot and colleagues, JAMA Psychiatry).
Semaglutide, 2026 (Denmark). The biggest semaglutide trial so far. 108 adults with alcohol use disorder AND obesity, for 26 weeks, all having cognitive behavioural therapy. Heavy drinking days fell by 41 percentage points on semaglutide, against 26 on a dummy injection (Klausen and colleagues, The Lancet). But it was one centre, only people with obesity, and no follow-up afterwards.
Oral semaglutide, 2026 (US). 50 adults for eight weeks. Its main measures, lab-measured craving and drinks per day, didn't differ from placebo. But there were fewer heavy drinking days (Schacht and colleagues, American Journal of Psychiatry).
Then there are the big studies of health records:
In the US, among around 84,000 people with obesity, those on semaglutide were 50% to 56% less likely to get a new or repeat alcohol use disorder diagnosis within a year than those on other weight-loss medicines (Wang and colleagues, 2024).
In Sweden, a study of 227,866 people with alcohol use disorder linked periods on semaglutide with a 36% lower risk of hospital admission for alcohol, and liraglutide with 28% (Lähteenvuo and colleagues, 2025).
Big numbers. But they show a link, not cause and effect. The study's lead author said the results should be "taken with a grain of salt", and both teams called for proper trials.
Read that again... Promising. Early. And small. The longest of these trials lasted 26 weeks. Nobody yet knows what happens to drinking over years, or after the injections stop.
Is naltrexone better than Ozempic for drinking less?
Honestly? Nobody can say yet. They've never been tested against each other. The evidence is a different SHAPE.
Naltrexone has decades of trials. A Cochrane review of 50 trials, with 7,793 people, found it lowered the risk of returning to heavy drinking (to 83% of the risk on a dummy pill). A real effect. Not a large one. And it varies from person to person.
GLP-1 medicines have a few small trials and some striking record studies, mostly in people with diabetes or obesity. The researchers behind the Swedish study say proper trials are urgently needed.
Different medicines, different bodies, different goals. Which one, if any, is right for you is a prescriber's call.
If Ozempic helps my drinking, do I need naltrexone?
Not necessarily. And not automatically.
If you're on a GLP-1 medicine and you're drinking less, tell your prescriber. It's useful for them to know. And hold a few things in mind:
It isn't prescribed for your drinking. Your prescription is for diabetes or weight. If that changes, or stops, nobody yet knows what happens to the drinking.
The NHS says it's best not to drink alcohol on semaglutide, because it can make nausea and vomiting worse.
Taking both is being studied, not settled. A small US trial of semaglutide plus naltrexone is planned to run from late 2026 to 2028. Combining medicines is your prescriber's decision, not something to try on your own.
And one thing no medicine does, tablet or injection...
It doesn't change our habits.
Over time, a medicine can quieten the desire. But the Friday nights, the stress, the routines built around a drink over years? That's the real work. And it's where support makes the difference: why support matters.
Had weight-loss surgery? That's its own conversation: Alcohol after weight-loss surgery.
What medicines ARE used for alcohol in the UK?
There are four main medicines for alcohol in the UK:
Acamprosate and naltrexone: the first-line options to help people stay stopped. Compared side by side: Acamprosate vs naltrexone.
Nalmefene (Selincro): licensed to help some people with alcohol dependence cut down, with ongoing support, and recommended by NICE as an option.
Disulfiram: usually second line. It causes an unpleasant reaction if you drink.
If you want to drink less rather than stop, say so to your doctor. It changes the conversation.
What about side effects?
In brief.
Naltrexone: the UK product information lists nausea, headache, trouble sleeping, anxiety and restlessness among the very common ones.
Semaglutide: in the 2026 Lancet trial, side effects were mostly mild to moderate, short-lived stomach and gut problems.
If anything worries you, speak to your prescriber or pharmacist. The full list, in plain English: Naltrexone side effects (UK).
Common questions
Is naltrexone the same as Ozempic?
No. Naltrexone is an opioid blocker, licensed in the UK for alcohol. Ozempic is semaglutide, a GLP-1 medicine licensed for type 2 diabetes.
Is naltrexone an anti-drinking medication?
It's one of four main medicines used for alcohol in the UK. It doesn't make you ill if you drink. It dampens part of the reward.
Will naltrexone help me lose weight?
Not on its own. Mysimba, a weight-loss tablet, combines it with bupropion; NICE doesn't recommend it on the NHS.
Can I get Ozempic for my drinking?
Not for drinking alone. In the UK, Ozempic is prescribed for type 2 diabetes, Wegovy for weight, and Mounjaro for either. Please don't buy them without a prescription: the NHS warns some websites sell fake weight-loss medicines. The same goes for naltrexone: here's how to check an online prescriber.
What about The Sun's "Ozempic for alcoholics" story?
In April 2026, The Sun ran a story calling naltrexone an "Ozempic for alcoholics". The man in it, Steve Roe, is one of our coaches. He came to The Sinclair Method after rehab hadn't worked for him, and he now coaches other people through it.
The medicine in that story is naltrexone. It isn't Ozempic, and it isn't a GLP-1 medicine. Headlines are written to grab attention, and timelines like "four days" or "a week" in press stories aren't typical. How it goes depends on the person, the support around them and their circumstances.
Read The Sun's article (it may be behind a paywall).
If you'd like support from us
Rethink Drink is a UK coaching service built around The Sinclair Method. Our programmes include a consultation with an independent prescriber, who decides whether treatment is suitable. Clinical oversight is provided by consultant psychiatrist Professor Jonathan Chick. Any prescription is dispensed by an independent partner pharmacy. Our coaches work with you, week by week, on everything around it.
And whatever happens, you can talk to someone today. Drinkline, the national alcohol helpline, is free and confidential: 0300 123 1110.
Please look after yourself
This page is here to help you understand your options. It isn't medical advice, and it can't replace a conversation with a doctor who can ask qualifying questions.
Before you change how much you drink or start any medication, speak to your GP or a prescriber.
We really hope this post helps. If you have any questions, you can contact us here.
The Rethink Drink team
Sources
MHRA Products. Adepend 50 mg film-coated tablets (naltrexone hydrochloride): Summary of Product Characteristics, listed with the other UK naltrexone products. products.mhra.gov.uk
MHRA Products. Mysimba 8 mg/90 mg prolonged-release tablets (naltrexone and bupropion): Summary of Product Characteristics, listed under naltrexone hydrochloride. products.mhra.gov.uk
NICE. Naltrexone and bupropion for managing overweight and obesity (TA494), December 2017. https://nice.org.uk/guidance/ta494/resources/naltrexonebupropion-for-managing-overweight-and-obesity-pdf-6052002403525. Summary by Lancashire and South Cumbria Medicines Management Group: https://lancsmmg.nhs.uk/medicines-library/naltrexonebupropion
NHS. Semaglutide (Ozempic, Wegovy, Rybelsus). Last reviewed May 2026. https://www.nhs.uk/medicines/semaglutide/
NHS. Tirzepatide (Mounjaro). Last reviewed May 2026. https://www.nhs.uk/medicines/tirzepatide/
European Medicines Agency. Ozempic (semaglutide): EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
Klausen MK and colleagues. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 2022. https://insight.jci.org/articles/view/159863
Hendershot CS and colleagues. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry, 2025. https://doi.org/10.1001/jamapsychiatry.2024.4789. Summary: https://immattersacp.org/weekly/archives/2025/02/18/2.htm
Klausen MK and colleagues. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet, 2026; 407(10540): 1687 to 1698. Abstract: https://www.drugsandalcohol.ie/45628/
Schacht J and colleagues (University of Colorado Anschutz). Oral semaglutide for alcohol use disorder: a randomized clinical trial. American Journal of Psychiatry, 2026. American Psychiatric Association news release: https://www.psychiatry.org/news-room/news-releases/new-research-oral-semaglutide-reduced-heavy-drinki
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications, 2024; 15. https://doi.org/10.1038/s41467-024-48780-6. Case Western Reserve University summary: https://case.edu/news/retrospective-study-based-electronic-health-records-finds-popular-diabetes-and-weight-loss-drugs-associated-reduction-incidence-and-recurrence-alcohol-use-disorder-least-half
Lähteenvuo M and colleagues. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry, 2025; 82(1): 94 to 98. https://doi.org/10.1001/jamapsychiatry.2024.3599. Abstract: https://www.drugsandalcohol.ie/42362. PsyPost report: https://www.psypost.org/semaglutide-and-liraglutide-linked-to-lower-alcohol-related-hospitalization-risk/
Rösner S and colleagues. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews, 2010 (CD001867). https://www.cochrane.org/CD001867/alcohol-opioid-antagonists-alcohol-dependence
Johns Hopkins University. Preliminary safety and efficacy of semaglutide and naltrexone combination therapy for alcohol use disorder (NCT07249554). https://trial.medpath.com/clinical-trial/0ea2eb13f988c1aa/nct07249554-semaglutide-naltrexone-combination-therapy-alcohol-use-disorder
Department of Health and Social Care. UK clinical guidelines for alcohol treatment, chapter 10: pharmacological interventions. https://www.gov.uk/guidance/clinical-guidelines-for-alcohol-treatment/10-pharmacological-interventions
NICE. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325). nice.org.uk
NICE. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325). https://www.nice.org.uk/guidance/ta325/chapter/4-consideration-of-the-evidence
The Pharmacist. Weight-loss drug reduces alcohol consumption, study finds. 12 May 2026. https://www.thepharmacist.co.uk/clinical/nutrition-and-gastroenterology/weight-loss-drug-reduces-alcohol-consumption-study-finds/

